Chemical Compound Review:
Lumeron 3-(4-hexoxy-1,2,5-thiadiazol- 3-yl)-1...
Synonyms:
XANOMELINE, Hexyloxy-TZTP, CHEMBL21536, SureCN121046, AG-D-64976, ...
- Effects of central muscarinic-1 receptor stimulation on blood pressure regulation. Medina, A., Bodick, N., Goldberger, A.L., Mac Mahon, M., Lipsitz, L.A. Hypertension (1997)
- The muscarinic M1/M4 receptor agonist xanomeline exhibits antipsychotic-like activity in Cebus apella monkeys. Andersen, M.B., Fink-Jensen, A., Peacock, L., Gerlach, J., Bymaster, F., Lundbaek, J.A., Werge, T. Neuropsychopharmacology (2003)
- Low-affinity M(2) receptor binding state mediates mouse atrial bradycardia: comparative effects of carbamylcholine and the M(1) receptor agonists sabcomeline and xanomeline. Stengel, P.W., Cohen, M.L. J. Pharmacol. Exp. Ther. (2001)
- Xanomeline, an M(1)/M(4) preferring muscarinic cholinergic receptor agonist, produces antipsychotic-like activity in rats and mice. Shannon, H.E., Rasmussen, K., Bymaster, F.P., Hart, J.C., Peters, S.C., Swedberg, M.D., Jeppesen, L., Sheardown, M.J., Sauerberg, P., Fink-Jensen, A. Schizophr. Res. (2000)
- Brain proton magnetic resonance spectroscopy (1H-MRS) in Alzheimer's disease: changes after treatment with xanomeline, an M1 selective cholinergic agonist. Satlin, A., Bodick, N., Offen, W.W., Renshaw, P.F. The American journal of psychiatry. (1997)
- Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. Bodick, N.C., Offen, W.W., Levey, A.I., Cutler, N.R., Gauthier, S.G., Satlin, A., Shannon, H.E., Tollefson, G.D., Rasmussen, K., Bymaster, F.P., Hurley, D.J., Potter, W.Z., Paul, S.M. Arch. Neurol. (1997)
- Efficacy of xanomeline in Alzheimer disease: cognitive improvement measured using the Computerized Neuropsychological Test Battery (CNTB). Veroff, A.E., Bodick, N.C., Offen, W.W., Sramek, J.J., Cutler, N.R. Alzheimer disease and associated disorders. (1998)
- Xanomeline and the antipsychotic potential of muscarinic receptor subtype selective agonists. Mirza, N.R., Peters, D., Sparks, R.G. CNS drug reviews. (2003)
- Differences in kinetics of xanomeline binding and selectivity of activation of G proteins at M(1) and M(2) muscarinic acetylcholine receptors. Jakubík, J., El-Fakahany, E.E., Dolezal, V. Mol. Pharmacol. (2006)
- The muscarinic agonist xanomeline increases monoamine release and immediate early gene expression in the rat prefrontal cortex. Perry, K.W., Nisenbaum, L.K., George, C.A., Shannon, H.E., Felder, C.C., Bymaster, F.P. Biol. Psychiatry (2001)
- On the unique binding and activating properties of xanomeline at the M1 muscarinic acetylcholine receptor. Christopoulos, A., Pierce, T.L., Sorman, J.L., El-Fakahany, E.E. Mol. Pharmacol. (1998)
- The safety and tolerance of xanomeline tartrate in patients with Alzheimer's disease. Sramek, J.J., Hurley, D.J., Wardle, T.S., Satterwhite, J.H., Hourani, J., Dies, F., Cutler, N.R. Journal of clinical pharmacology. (1995)
- Persistent binding and functional antagonism by xanomeline at the muscarinic M5 receptor. Grant, M.K., El-Fakahany, E.E. J. Pharmacol. Exp. Ther. (2005)
- Functional effects of the muscarinic receptor agonist, xanomeline, at 5-HT1 and 5-HT2 receptors. Watson, J., Brough, S., Coldwell, M.C., Gager, T., Ho, M., Hunter, A.J., Jerman, J., Middlemiss, D.N., Riley, G.J., Brown, A.M. Br. J. Pharmacol. (1998)
- Xanomeline: a novel muscarinic receptor agonist with functional selectivity for M1 receptors. Shannon, H.E., Bymaster, F.P., Calligaro, D.O., Greenwood, B., Mitch, C.H., Sawyer, B.D., Ward, J.S., Wong, D.T., Olesen, P.H., Sheardown, M.J. J. Pharmacol. Exp. Ther. (1994)
- Pharmacological analysis of the novel mode of interaction between xanomeline and the M1 muscarinic acetylcholine receptor. Christopoulos, A., Parsons, A.M., El-Fakahany, E.E. J. Pharmacol. Exp. Ther. (1999)
- Functional comparison of muscarinic partial agonists at muscarinic receptor subtypes hM1, hM2, hM3, hM4 and hM5 using microphysiometry. Wood, M.D., Murkitt, K.L., Ho, M., Watson, J.M., Brown, F., Hunter, A.J., Middlemiss, D.N. Br. J. Pharmacol. (1999)
- Neurochemical effects of the M1 muscarinic agonist xanomeline (LY246708/NNC11-0232). Bymaster, F.P., Wong, D.T., Mitch, C.H., Ward, J.S., Calligaro, D.O., Schoepp, D.D., Shannon, H.E., Sheardown, M.J., Olesen, P.H., Suzdak, P.D. J. Pharmacol. Exp. Ther. (1994)
- M1 receptor agonist activity is not a requirement for muscarinic antinociception. Sheardown, M.J., Shannon, H.E., Swedberg, M.D., Suzdak, P.D., Bymaster, F.P., Olesen, P.H., Mitch, C.H., Ward, J.S., Sauerberg, P. J. Pharmacol. Exp. Ther. (1997)
- The muscarinic receptor agonist xanomeline has an antipsychotic-like profile in the rat. Stanhope, K.J., Mirza, N.R., Bickerdike, M.J., Bright, J.L., Harrington, N.R., Hesselink, M.B., Kennett, G.A., Lightowler, S., Sheardown, M.J., Syed, R., Upton, R.L., Wadsworth, G., Weiss, S.M., Wyatt, A. J. Pharmacol. Exp. Ther. (2001)
- High-performance liquid chromatographic assay for xanomeline, a specific M-1 agonist, and its metabolite in human plasma. Kasper, S.C., Bonate, P.L., DeLong, A.F. J. Chromatogr. B, Biomed. Appl. (1995)
- Determination of xanomeline (LY246708 tartrate), an investigational agent for the treatment of Alzheimer's disease, in rat and monkey plasma by capillary gas chromatography with nitrogen-phosphorus detection. Brown, T.J., Shipley, L.A. J. Chromatogr. B, Biomed. Appl. (1995)